Anti-FMC63 high-affinity rabbit monoclonal antibody and application thereof
By developing high-affinity rabbit monoclonal antibodies 6A7, 4G3 and 8D6, combined with flow cytometry detection, the limited problems of FMC63 antibody detection technology in CAR-T cell therapy were solved, and high-sensitivity detection was achieved to support CAR-T cells. Effective diagnosis and monitoring of therapy.
Patent Information
- Application Number
- CN202411256425.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing CAR-T cell therapy has limited detection technology for FMC63 antibodies, and it is difficult to provide high sensitivity and diversified detection methods, which affects the diagnosis and monitoring of treatment effects.
A high-affinity rabbit monoclonal antibodies against FMC63 were developed, and FMC63 was detected by flow cytometry to detect FMC63 antibody expression in CAR-T cells, providing a more sensitive detection method.
It realizes high sensitivity detection of FMC63 antibodies, supports effective diagnosis and monitoring of CAR-T cell therapy, provides a variety of detection options, and enhances the ability to evaluate the therapeutic effect.
Smart Images

Figure CN119060190A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a high-affinity rabbit monoclonal antibody against FMC63 and an application thereof. Background Art
[0002] In today's medical field, CAR-T cell therapy is a new breakthrough and new hope for tumor treatment. CD19 is currently the most widely used target in the field of CAR-T cell therapy. It is one of the effective and safe targets for treating tumor diseases such as B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL) and B-cell lymphoma. FMC63 antibody is a mouse monoclonal antibody targeting human CD19, which makes CAR-T cell therapy more precise and safe. The two anti-CD19 CAR-T cell drugs Kymriah and Yescarta approved by the FDA have demonstrated the practicality and value of FMC63 antibody. Based on the anti-CD19 FMC63 antibody, the therapeutic effect of the corresponding CAR-T cell therapy can be detected and verified by detecting the expression of FMC63 antibody. Summary of the invention
[0003] The present invention provides a high-affinity rabbit monoclonal antibody against FMC63 and an application method thereof. By utilizing the rabbit single B cell antibody development technology, three antibodies that specifically recognize the FMC63 antibody were obtained, named 6A7, 4G3 and 8D6, respectively, which can be used for the Flow Cytometry (FCM) method to detect the expression of Anti-CD19 (FMC63) CAR. The emergence of this innovative antibody provides more options and possibilities for the detection of CAR-T cell therapy. The technical solution of the present invention is specifically implemented by the following technologies.
[0004] A high affinity rabbit monoclonal antibody against FMC63, including monoclonal antibody 6A7, monoclonal antibody 4G3 or monoclonal antibody 8D6;
[0005] The amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 on the heavy chain of the monoclonal antibody 6A7 are respectively as shown in SEQ ID NO.1-3, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.1-3; the amino acid sequences of the complementary determining regions CDR1 and CDR3 on the light chain of the monoclonal antibody 6A7 are respectively as shown in SEQ ID NO.4 and SEQ ID NO.5, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.4-5; the amino acid sequence of the complementary determining region CDR2 on the light chain of the monoclonal antibody 6A7 is RAS;
[0006] The amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 on the heavy chain of the monoclonal antibody 4G3 are respectively as shown in SEQ ID NO.10-12, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.10-12; the amino acid sequences of the complementary determining regions CDR1 and CDR3 on the light chain of the monoclonal antibody 4G3 are respectively as shown in SEQ ID NO.13 and SEQ ID NO.14, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.13-14; the amino acid sequence of the complementary determining region CDR2 on the light chain of the monoclonal antibody 4G3 is AAS;
[0007] The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain of the monoclonal antibody 8D6 are respectively as shown in SEQ ID NO.19-21, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.19-21; the amino acid sequences of the complementary determining regions CDR1 and CDR3 on the light chain of the monoclonal antibody 8D6 are respectively as shown in SEQ ID NO.22 and SEQ ID NO.23, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.22-23, and the amino acid sequence of the complementary determining region CDR2 on the light chain of the monoclonal antibody 8D6 is RAS.
[0008] Furthermore, the amino acid sequence of the heavy chain variable region of the monoclonal antibody 6A7 is shown in SEQ ID NO.6, and the amino acid sequence of the light chain variable region of the monoclonal antibody 6A7 is shown in SEQ ID NO.7.
[0009] Furthermore, the amino acid sequence of the heavy chain of the monoclonal antibody 6A7 is shown in SEQ ID NO.8, and the amino acid sequence of the light chain of the monoclonal antibody 6A7 is shown in SEQ ID NO.9.
[0010] Furthermore, the amino acid sequence of the heavy chain variable region of the monoclonal antibody 4G3 is shown in SEQ ID NO.15, and the amino acid sequence of the light chain variable region of the monoclonal antibody 4G3 is shown in SEQ ID NO.16.
[0011] Furthermore, the amino acid sequence of the heavy chain of the monoclonal antibody 4G3 is shown in SEQ ID NO.17, and the amino acid sequence of the light chain of the monoclonal antibody 4G3 is shown in SEQ ID NO.18.
[0012] Furthermore, the amino acid sequence of the heavy chain variable region of the monoclonal antibody 8D6 is shown in SEQ ID NO.24, and the amino acid sequence of the light chain variable region of the monoclonal antibody 8D6 is shown in SEQ ID NO.25.
[0013] Furthermore, the amino acid sequence of the heavy chain of the monoclonal antibody 8D6 is shown in SEQ ID NO.24, and the amino acid sequence of the light chain of the monoclonal antibody 8D6 is shown in SEQ ID NO.25.
[0014] The present invention also provides a substance, which comprises any one of the following aspects:
[0015] (1) A nucleic acid molecule or a vector comprising the nucleic acid molecule, wherein the nucleic acid encodes the high-affinity rabbit monoclonal antibody described in any one of the above items;
[0016] (2) A modified cell or recombinant strain, wherein the modified cell or recombinant strain is used to express the high-affinity rabbit monoclonal antibody described in any one of the above items;
[0017] (3) An antibody derivative, comprising any of the high-affinity rabbit monoclonal antibodies described above;
[0018] (4) A pharmaceutical composition comprising a therapeutically effective amount of any of the high-affinity rabbit monoclonal antibodies described above, or the antibody derivatives thereof;
[0019] (5) A detection product, comprising the high-affinity rabbit monoclonal antibody described in any one of the above items, or the nucleic acid molecule, or the vector, or the antibody derivative.
[0020] The present invention also provides the application of the above-mentioned high-affinity rabbit monoclonal antibody against FMC63, and the application includes any one of the following aspects:
[0021] (1) Detection of FMC63 antibody expression for purposes other than disease diagnosis and treatment;
[0022] (2) Used for testing the efficacy of CAR-T cells expressing FMC63 antibodies for purposes other than disease diagnosis and treatment;
[0023] (3) Used to prepare products for detecting the expression of FMC63 antibodies; or, used to prepare products for regulating the activity of FMC63 antibodies; or, used to prepare products for detecting the efficacy of CAR-T cells expressing FMC63 antibodies.
[0024] Furthermore, flow cytometry was used to detect the expression of FMC63 antibody in CAR-T cells.
[0025] Furthermore, the product is a detection reagent, a detection kit, a detection test strip, a detection probe or a detection chip.
[0026] The high-affinity rabbit monoclonal antibody against FMC63 provided by the present invention is not limited to detecting the expression of FMC63 antibodies in CAR-T cells. Based on its high affinity for FMC63, the monoclonal antibody provided by the present invention can also be used for qualitative / quantitative detection of FMC63 antibodies in any other environment. Correspondingly, a product for detecting the expression of FMC63 antibodies can be prepared using a high-affinity rabbit monoclonal antibody against FMC63.
[0027] It should also be pointed out that in the above-mentioned application provided by the present invention, the high-affinity rabbit monoclonal antibody against FMC63 can not only detect the expression of FMC63 antibodies in CAR-T cells, but also be used for auxiliary detection and diagnosis of the disease condition or efficacy of CAR-T cell therapy for certain CD19-related cancers.
[0028] The present invention also provides a product for detecting the expression of FMC63 antibodies in CAR-T cells, wherein the product is a detection reagent, a detection kit, a detection test strip or a detection chip.
[0029] Compared with the prior art, the present invention is beneficial in that:
[0030] 1. The present invention provides a set of high-affinity monoclonal antibodies 6A7, 4G3 and 8D6 against FMC63 for the detection technology of FMC63 antibody expression in CAR-T cell therapy for CD19. After testing, the affinity constant of monoclonal antibody 6A7 for FMC63 antibody binding is 7.36E-11, the affinity constant of monoclonal antibody 4G3 for FMC63 antibody binding is 9.45E-11, and the affinity constant of monoclonal antibody 8D6 for FMC63 antibody binding is 4.71E-11. This is of great significance for the diagnosis of the efficacy of CAR-T cell therapy in the treatment of cancer.
[0031] 2. The present invention uses flow cytometry to detect the expression of FMC63 in Anti-CD19 (FMC63) transfected cells (i.e., CAR-T cells), which can be used for high-sensitivity detection of FMC63. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 These are the test results of 3 antibody titers.
[0033] Figure 2 The following are the flow cytometry results of three antibodies.
[0034] Figure 3 The following are the results of affinity testing of three antibodies. DETAILED DESCRIPTION
[0035] The technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0036] In the implementation cases of the present invention, the term "nucleic acid (molecule)" may include a coding nucleic acid or a nucleic acid that also includes additional coding and / or non-coding sequences. The DNA form of the nucleic acid of the present invention includes but is not limited to cDNA, genomic DNA or artificially synthesized DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand. The nucleic acid encoding the high-affinity rabbit monoclonal antibody or its antigen-binding fragment described in the present invention includes but is not limited to a coding sequence that only encodes the structure of a mature high-affinity rabbit monoclonal antibody or its antigen-binding fragment; a coding sequence and various additional coding sequences that encode a mature high-affinity rabbit monoclonal antibody or its antigen-binding fragment; a coding sequence (and optional additional coding sequences) and non-coding sequences that encode the structure of a mature high-affinity rabbit monoclonal antibody or its antigen-binding fragment, etc.
[0037] In some embodiments of the present invention, the full-length nucleic acid sequence of the high-affinity rabbit monoclonal antibody or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. Once the relevant sequence is obtained, the relevant sequence can be obtained in large quantities by recombination. Generally, it is cloned into a vector, then transferred into cells, and then the relevant sequence is isolated from the host cells after proliferation by conventional methods. The biological molecules involved in the present invention (nucleic acids, high-affinity rabbit monoclonal antibodies and antigen-binding fragments thereof, etc.) include biological molecules in isolated form.
[0038] The vectors include viral vectors (such as adenoviral vectors, retroviral vectors, adeno-associated viral vectors) and non-viral vectors (plasmids, transposon vectors).
[0039] In some preferred embodiments, the vector is an expression vector.
[0040] The terms "vector," "cloning vector," and "expression vector" refer to a vehicle that can introduce DNA or RNA sequences into a host cell in a manner that transforms the host and promotes the expression (eg, transcription and translation) of the introduced sequence.
[0041] Other examples of plasmids include replicating plasmids comprising an origin of replication, or integrating plasmids.
[0042] The vector may be a recombinant expression vector or a cloning vector. The vector provided by the present invention (eg, an expression vector) contains the nucleic acid sequence provided by the present invention encoding the antibody, at least one promoter operably connected to the nucleic acid sequence and / or at least one selection marker.
[0043] Examples of vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papovaviruses, lambda phage, M13 phage, plasmids, and the like.
[0044] The "transformed cells" provided by the present invention refer to the introduction of "foreign" (i.e., external or extracellular) genes or DNA or RNA sequences into host cells so that the host cells express the introduced genes or sequences to produce substances of interest, usually proteins encoded by the genes or introduced sequences. Host cells that receive and express the introduced DNA or RNA have been "transformed."
[0045] In a specific embodiment of the present invention, the host cell includes but is not limited to mammalian cells, insect cells, plant cells, fungal cells, prokaryotic cells and the like.
[0046] The present invention provides an antibody derivative, which comprises the high-affinity rabbit monoclonal antibody provided by the present invention, directly or indirectly connected to a complex formed by a connectable substance.
[0047] The attachable species include a detectable label, a drug, a toxin, a cytokine, a radionuclide or an enzyme.
[0048] In a specific embodiment of the present invention, the connectable substance is selected from: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer tomography) contrast agents, or enzymes capable of producing detectable products, radionuclides, biological toxins, cytokines (such as IL-2, etc.), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles / nanorods, viral particles, liposomes, nanomagnetic particles, prodrug activating enzymes (such as DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL), chemotherapeutic agents (such as cisplatin)) or any form of nanoparticles, etc.
[0049] The term "detectable marker" refers to any part that generates a measurable signal by a change in the optical, electrical or other physical index of the molecular state coupled to the part. Such physical indexes include spectral, photochemical, biochemical, immunochemical, electromagnetic, radiochemical and chemical means, such as but not limited to fluorescence, chemiluminescence and chemiluminescence. When used with respect to a labeled detection agent, a "direct label" is a detectable label attached to the detection agent by any means. When used with respect to a labeled detection agent, an "indirect label" is a detectable label that specifically binds to the detection agent. Therefore, an indirect label includes the following parts: the specific binding partner of the detection agent. Biotin and avidin are examples of such parts that are used, for example, by contacting a biotinylated antibody with a labeled avidin to produce an indirectly labeled antibody.
[0050] The pharmaceutical composition provided by the present invention includes a pharmaceutically acceptable carrier or excipient. In some embodiments, the excipient includes a pharmaceutically acceptable solvent, a dispersant, an additive, a plasticizer, etc. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable carrier medium. The formulated pharmaceutical composition can be administered by conventional routes, including but not limited to: intratumoral, intraperitoneal, intravenous, or topical administration.
[0051] In other embodiments, the pharmaceutical composition is an aqueous pharmaceutical composition (e.g., an aqueous solution), or the high affinity rabbit monoclonal antibody and salt are provided in water without a buffer, or include an aqueous buffer or other type of solvent (e.g., an organic solvent).
[0052] The term "effective amount" as used herein refers to an amount sufficient to achieve a beneficial or desired result. A "therapeutically effective amount" is an amount that achieves a desired therapeutic effect. This amount may be the same or different from a preventive effective amount, which is the amount required to prevent the onset of a disease or disease symptoms. An effective amount may be administered, applied or dosed once or more. The "therapeutically effective amount" (i.e., effective dose) of a therapeutic compound is determined according to the selected therapeutic compound. For example, the composition may be administered once or more per day, once or more per week, once or more per month, or once or more per year. Certain factors may affect the dosage and timing required for the effective treatment of a subject, including but not limited to the severity of the disease or illness, previous treatment, the general health and / or age of the subject, and other diseases present.
[0053] 1. Animal immunization
[0054] In order to obtain rabbit monoclonal antibodies that recognize FMC63 antibodies, the present invention uses FMC63 antibodies as immunogens to immunize two New Zealand white rabbits, with each rabbit immunized with 250 μg. The immunization method is:
[0055] For the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant to make an emulsion, which was injected subcutaneously at multiple points in the abdomen and back; at intervals of 2 weeks, 250 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant to make an emulsion, which was injected subcutaneously at multiple points in the abdomen and back; three booster immunizations were performed; after three booster immunizations, the serum titer was determined by ELISA, and rabbits with high serum titers were taken for booster immunization once with 250 μg of the immunogen injected subcutaneously at multiple points, and the spleen was taken out three days later.
[0056] 2. Isolation and collection of peripheral blood PBMC
[0057] Aseptically collect rabbit peripheral anticoagulated blood, separate PBMCs by Ficoll density gradient centrifugation, wash cells twice with sterile PBS, count suspended cells, and store PBMCs in liquid nitrogen for long term storage.
[0058] 3. Single B cell flow cytometry sorting and culture
[0059] (1) Resuspend PBMC in PBS and adjust the cell concentration to 1×10 7 cells / ml, flow cytometry antibodies were added according to the volume of resuspended cells to stain B cells, Goat Anti-rabbit IgM FITC (goat anti-rabbit IgM secondary antibody) and FMC63 antibody specific-APC were added at a ratio of 1:100, respectively; blank control and single staining control were set up, and incubated at room temperature in the dark for 30 minutes; washed twice with PBS, and centrifuged at 300g for 5 minutes at 4°C.
[0060] (2) Resuspend the cells in PBS and filter them with a 100-mesh filter before loading. 5 minutes before loading, add 2% PI for staining to remove dead cells. Use the control to adjust the voltage and set the fluorescence compensation. Use FSC-A / SSC-A to select lymphocytes and use FSC-W / FSC-A to remove adherent cells. IgM-negative, antigen-positive, and PI-negative B cells were selected.
[0061] (3) By flow cytometry, one B cell was added to each well of a 96-well plate containing 100 μl of complete 1640 medium (containing 10% FBS, 1% penicillin-streptomycin, 1% glutamine, and 2 μg / mL human IL-2). The 96-well plate was centrifuged at 300 g for 5 min and incubated at 37°C with 5% CO. 2 Culture for 7 days.
[0062] 4. Elisa screening of positive clones
[0063] The screening method is as follows:
[0064] (1) Coating: Take 5 μg / ml FMC63 antibody and coat at 100 μl / well at 4°C overnight.
[0065] (2) Blocking: 3% BSA-PBST was added at 300 μl / well and blocked at 37°C for 1.5 h.
[0066] (3) Washing: Take PBST and wash twice with 300 μl / well.
[0067] (4) Sample addition: Take 50 μl of the culture supernatant from a 96-well plate, dilute it 1:1 with 50 μl of PBS, and incubate at 37°C for 1 h at a rate of 100 μl / well.
[0068] (5) Washing: Take PBST and wash three times with 300 μl / well.
[0069] (6) Add secondary antibody: Add Goat-anti Rabbit IgG secondary antibody at 100 μl / well and incubate at 37°C for 30 min.
[0070] (7) Washing: Take PBST and wash three times with 300 μl / well.
[0071] (8) Add color developing agent: Add TMB Substrate Solution at 100 μl / well and develop color at 37°C for 5-10 min.
[0072] (9) Termination: Add 2M HCl, 50 μl / well to terminate the reaction.
[0073] (10) Reading: OD 450 -OD 630 .
[0074] 5. Sequencing and expression of specific rabbit monoclonal antibodies
[0075] B cells corresponding to Elisa-positive antibodies were collected, and RNA was extracted and reverse transcribed into cDNA using conventional methods.
[0076] The heavy chain variable region gene amplification primer sequences are:
[0077] Forward primer: 5'-aagcttgccaacatgcagactgggctgcgctggcttc-3', as shown in SEQ ID NO.28.
[0078] Reverse primer: 5'-ccattggtgagcatgcccgag-3', as shown in SEQ ID NO.29.
[0079] The primers for light chain variable region gene amplification are:
[0080] Forward primer: 5'-aagcttgctaccatgcacagagggcccccactc-3', as shown in SEQ ID NO.30.
[0081] Reverse primer: 5'-cagtgtctgctgaggatgtaggtac-3', as shown in SEQ ID NO.31.
[0082] The heavy and light chain variable region genes were amplified using cDNA as a template. The PCR reaction system was: 95°C for 3 min, (95°C for 1 min, 58°C for 30 s, 72°C for 1 min) for 25 cycles, and finally 72°C for 5 min. The PCR products were recovered and purified.
[0083] The heavy and light chain variable region genes of the rabbit recombinant monoclonal antibody were connected to the pMD20-T vector for transformation and plate coating.
[0084] Finally, colony PCR is performed to verify the positive clones, and the positive clones are sequenced to obtain the variable region gene sequence of the rabbit monoclonal antibody.
[0085] The amino acid sequence of the heavy chain complementary determining region CDR1 of the monoclonal antibody 6A7 is GFSLSTYH, as shown in SEQ ID NO.1.
[0086] The amino acid sequence of the heavy chain complementary determining region CDR2 of monoclonal antibody 6A7 is INSWGIS, as shown in SEQ ID NO.2.
[0087] The amino acid sequence of the heavy chain complementary determining region CDR3 of monoclonal antibody 6A7 is VRGWDALDP, as shown in SEQ ID NO.3.
[0088] The amino acid sequence of the light chain complementary determining region CDR1 of monoclonal antibody 6A7 is QSISSY, as shown in SEQ ID NO.4.
[0089] The amino acid sequence of the light chain complementary determining region CDR3 of monoclonal antibody 6A7 is QCTYYGVTYGNA, as shown in SEQ ID NO.5.
[0090] The amino acid sequence of the heavy chain variable region of monoclonal antibody 6A7 is:
[0091] MKHLWFFLLLVAAPRWVLSQSLEESGGRLVTPGTPLTLTCTASGFSLSTYHMNWV RQAPGKGLEWIGIINSWGISYYASWAKGRFTISKTSTTVDLRITSPTTEDTATYFCVRGW DALDPWGPGILVTVSS, as shown in SEQ IDNO.6.
[0092] The amino acid sequence of the light chain variable region of monoclonal antibody 6A7 is:
[0093] MVLQTQVFISLLLWISGAYGDVVMTQTPASVSEPVGGTVTIKCQASQSISSYLSWY QQKPGQPPKLLIYRASTLESGVPSRFKGSGSGTEYTLTISDLECADAATYYCQCTYYGVT YGNAFGGGTEVVVK, as shown in SEQ IDNO.7.
[0094] The amino acid sequence of the heavy chain of monoclonal antibody 6A7 is:
[0095] MKHLWFFLLLVAAPRWVLSQSLEESGGRLVTPGTPLTLTCTASGFSLSTYHMNWVRQAPGKGLEWIGIINSWGISYYASWAKGRFTISKTSTTVDLRITSPTTEDTATYFCVRGWD ALDPWGPGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, such as SEQ Shown as ID NO.8.
[0096] The amino acid sequence of the light chain of monoclonal antibody 6A7 is:
[0097] MVLQTQVFISLLLWISGAYGDVVMTQTPASVSSEPVGGTVTIKCQASQSISSYLSWYQQKPGQPPKLLIYRASTLESGVPSRFKGSGSGTEYTLTISDLECADAATYYCQCTYYGVTYGNAF GGGTEVVVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKVYACEVTHQGLSSPVTKSFNRGEC, as in SEQ Shown as ID NO.9.
[0098] The amino acid sequence of the heavy chain complementary determining region CDR1 of monoclonal antibody 4G3 is GFSLSRYY, as shown in SEQ ID NO.10.
[0099] The amino acid sequence of the heavy chain complementary determining region CDR2 of monoclonal antibody 4G3 is IYTDGIT, as shown in SEQ ID NO.11.
[0100] The amino acid sequence of the heavy chain complementary determining region CDR3 of monoclonal antibody 4G3 is ARAYDGFDL, as shown in SEQ ID NO.12.
[0101] The amino acid sequence of the light chain complementary determining region CDR1 of the monoclonal antibody 4G3 is ENIYNS, as shown in SEQ ID NO.13.
[0102] The amino acid sequence of the light chain complementary determining region CDR3 of monoclonal antibody 4G3 is QTYGPSRGA, as shown in SEQ ID NO.14.
[0103] The amino acid sequence of the heavy chain variable region of monoclonal antibody 4G3 is:
[0104] MKHLWFFLLLVAAPRWVLSQSVEESGGRLVTPGTPLTLTCTVSGFSLSRYYMSWV RQAPGKGLEWIGSIYTDGITYYASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARAY DGFDLWGPGTLVTVSS, as shown in SEQ IDNO.15.
[0105] The amino acid sequence of the light chain variable region of monoclonal antibody 4G3 is:
[0106] MVLQTQVFISLLLWISGAYGDIVMTQTPASVEAAVGGTVTINCQASENIYNSLAWY QQKPGQRPKLLIYAASTLASEVSSRFTGDGSGTQFSLTISDLDCADAATYYCQTYGPSRG AFGGGTEVVVK, as shown in SEQ ID NO.16.
[0107] The amino acid sequence of the heavy chain of monoclonal antibody 4G3 is:
[0108] MKHLWFFLLLVAAPRWVLSQSVEESGGRLVTPGTPLTLTCTVSGFSLSRYYMSWVRQAPGKGLEWIGSIYTDGITYYASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARAYD GFDLWGPGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, such as SEQ Shown as ID NO.17.
[0109] The amino acid sequence of the light chain of monoclonal antibody 4G3 is:
[0110] MVLQTQVFISLLLWISGAYGDIVMTQTPASVEAAVGGTVTINCQASENIYNSLAWYQQKPGQRPKLLIYAASTLASEVSSRFTGDGSGTQFSLTISDLDCADAATYYCQTYGPSRGAFG GGTEVVVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC, as in SEQ Shown as ID NO.18.
[0111] The amino acid sequence of the heavy chain complementary determining region CDR1 of monoclonal antibody 8D6 is: GIDLSSYA, as shown in SEQ ID NO.19.
[0112] The amino acid sequence of the heavy chain complementary determining region CDR2 of monoclonal antibody 8D6 is INTGDST, as shown in SEQ ID NO.20.
[0113] The amino acid sequence of the heavy chain complementary determining region CDR3 of monoclonal antibody 8D6 is ASSSPGYSAATFDL, as shown in SEQ ID NO.21.
[0114] The amino acid sequence of the light chain complementary determining region CDR1 of monoclonal antibody 8D6 is QSVYDNVR, as shown in SEQ ID NO.22.
[0115] The amino acid sequence of the light chain complementary determining region CDR3 of monoclonal antibody 8D6 is QGYYSGYIYV, as shown in SEQ ID NO.23.
[0116] The amino acid sequence of the heavy chain variable region of monoclonal antibody 8D6 is:
[0117] MKHLWFFLLLVAAPRWVLSQSVEESGGRLVTPGTPLTLTCTASGIDLSSYAMGWV RQAPGKGLEYIGFINTGDSTYSASWAKGRFTISKTSSTTVDLKITSPTTEDTATYFCASSSP GYSAATFDLWGQGTLVTVSS, as shown in SEQID NO.24.
[0118] The amino acid sequence of the light chain variable region of monoclonal antibody 8D6 is:
[0119] MVLQTQVFISLLLWISGAYGAQVLTQTPSPVSAAVGGTVTISCQASQSVYDNVRLA WYQQKPGQPPKLLIYRASNLASGVPSRFKGSGSGTQFTLTISEVQCDDAATYYCQGYYS GYIYVFGGGTEVVVK, as shown in SEQ IDNO.25.
[0120] The amino acid sequence of the heavy chain of monoclonal antibody 8D6 is:
[0121] MKHLWFFLLLVAAPRWVLSQSVEESGGRLVTPGTPLTLTCTASGIDLSSYAMGWVRQAPGKGLEYIGFINTGDSTYSASWAKGRFTISKTSSTTVDLKITSPTTEDTATYFCASSSPG YSAATFDLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, such as SEQ Shown as ID NO.26.
[0122] The amino acid sequence of the light chain of monoclonal antibody 8D6 is:
[0123] MVLQTQVFISLLLWISGAYGAQVLTQTPSPVSAAVGGTVTISCQASQSVYDNVRLAWYQQKPGQPPKLLIYRASNLASGVPSRFKGSGSGTQFTLTISEVQCDDAATYYCQGYYSGYIYVF GGGTEVVVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKVYACEVTHQGLSSPVTKSFNRGEC, as in SEQ Shown as ID NO.27.
[0124] The heavy chain variable region gene of the correctly sequenced rabbit monoclonal antibody was subcloned into PATX1-h1, and the light chain variable region gene was subcloned into PATX1-hk. The two plasmids were co-transfected into Xten CHO cells. After 72 hours of transfection, the cells were removed by centrifugation and the culture supernatant was purified with Protein A resin.
[0125] 6. Recombinant expression antibody titer detection
[0126] The detection method is as follows:
[0127] (1) Antigen coating: 5 μg / ml FMC63 antibody (CBS) was added and coated at 100 μl / well at 4°C overnight.
[0128] (2) Blocking: 3% BSA-PBST was added at 300 μl / well and blocked at 37°C for 1.5 h.
[0129] (3) Washing: Take PBST and wash three times with 300 μl / well.
[0130] (4) The primary antibody detection concentration starts at 1 μg / ml and is diluted 2-fold in sequence to make 7 dilution points, namely 1 μg / ml, 0.5 μg / ml, 0.25 μg / ml, 0.125 μg / ml, 0.0625 μg / ml, 0.03125 μg / ml and 0.015625 μg / ml. Add 100 μl PBS to the last well as well 0.
[0131] (5) Washing: Take PBST and wash the plate three times with 300 μl / well.
[0132] (6) Secondary antibody, Peroxidase-conjugated Affinipure Goat Anti-Rabbit (H+L), 1:10000 (PBS), 100 μl / well, 37°C, 30 min.
[0133] (7) Washing: Wash the plate 3 times with 300 μl / well of PBST.
[0134] (8) TMB color development: 100 μl / well, 37°C for 10 min.
[0135] (9) Termination: Add 2M HCl, 50 μl / well to terminate the reaction.
[0136] (10) Reading: OD 450 -OD 630 .
[0137] ELISA results Figure 1 As shown in Table 1 below, 6A7, 4G3 and 8D6 all have high binding activity to the FMC63 antibody.
[0138] Table 1
[0139] 6A7 4G3 8D6 EC50(ng / ml) 11.50 29.46 23.70
[0140] 7. Flow cytometry
[0141] (1) Cell preparation: Add appropriate amount of PBS to Anti-CD19 (FMC63) CAR transfected cells / empty cells and resuspend them. Divide them into tubes, 100ul / tube.
[0142] (2) Primary antibody incubation: Add 0.5 μg of Anti-FMC63 primary antibody to the cells, mix well, and incubate at room temperature for 30 min.
[0143] (3) Cell washing: Add 1 mL of PBS / tube, centrifuge at 1500 rpm for 3 min, and remove the supernatant.
[0144] (4) Fluorescent secondary antibody incubation: Add 1:100 diluted Goat anti Rabbit-FITC, mix well, and incubate at room temperature for 30 min.
[0145] (5) Cell washing: Add 1 mL of PBS / tube, centrifuge at 1500 rpm for 3 min, and remove the supernatant.
[0146] (6) Add appropriate amount of PBS and test on the machine.
[0147] The flow cytometry results are as follows Figure 2 As shown, it can be seen that after Anti-CD19 (FMC63) CAR transfected cells, the positive rate of cells expressing Anti-CD19 (FMC63) was above 99%, indicating that Anti-CD19 (FMC63) CAR was successfully constructed.
[0148] 8. Affinity detection of recombinant expressed antibodies
[0149] (1) Turn on the Biacore T200 instrument according to standard operating procedures.
[0150] (2) Open the Biacore T200 control software and install the CM5 chip according to the standard process
[0151] (3) Prepare to begin the formal experiment. Start the run. The buffer will flush the flow system inside the entire system at a high flow rate and prepare for standby.
[0152] (4) Select the appropriate test tube module according to the sample size.
[0153] (5) Start capturing the chip, and the coupling buffer is HEPES-ET. According to the sample rack position table, prepare sufficient volume of sample, EDC / NHS, and blocking buffer. Place the Anti-FMC63 Ab on the test tube rack according to the corresponding position required by the software. Cover the test tube rack lid and return the sample rack to the sample chamber. The system officially automatically runs the coupling program.
[0154] (6) After coupling was completed, sample detection was started. According to the standard procedure, the ligand Anti-FMC63 Ab contact time was set to 30 s, the flow rate was set to 10 μl / min, the analyte Ab, the contact time was set to 120 s, the flow rate was set to 30 μl / min, the dissociation time was set to 300 s, and the regeneration condition was set to 3 M magnesium chloride with a regeneration time of 30 s.
[0155] (7) Prepare the corresponding samples to be tested as required, place them in the sample compartment according to the location requirements, and start the automatic running program for testing.
[0156] (8) Result analysis: Based on the running results, data fitting analysis is performed to obtain the final affinity fitting KD value.
[0157] like Figure 3 As shown in the following Table 2, it can be seen that monoclonal antibody 6A7, monoclonal antibody 4G3 or monoclonal antibody 8D6 has a very high affinity.
[0158] Table 2
[0159] Antigen & Antibody ka(1 / Ms) kd(1 / s) KD(M) Anti-FMC63 Ab&6A7 1.29E+05 9.52E-06 7.36E-11 Anti-FMC63Ab&4G3 1.62E+05 1.53E-06 9.45E-11 Anti-FMC63Ab&8D6 2.66E+05 1.25E-06 4.71E-11
[0160] The above specific embodiments describe the implementation of the present invention in detail, but the present invention is not limited to the specific details in the above embodiments. Within the scope of the claims and technical concept of the present invention, the technical solution of the present invention can be modified and changed in many simple ways, and these simple modifications all belong to the protection scope of the present invention.
Claims
1. A high-affinity rabbit monoclonal antibody against FMC63, characterized in that: including monoclonal antibody 6A7, monoclonal antibody 4G3 or monoclonal antibody 8D6; The amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 on the heavy chain of the monoclonal antibody 6A7 are respectively as shown in SEQ ID NO.1-3, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.1-3; the amino acid sequences of the complementary determining regions CDR1 and CDR3 on the light chain of the monoclonal antibody 6A7 are respectively as shown in SEQ ID NO.4 and SEQ ID NO.5, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.4-5; the amino acid sequence of the complementary determining region CDR2 on the light chain of the monoclonal antibody 6A7 is RAS; The amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 on the heavy chain of the monoclonal antibody 4G3 are respectively as shown in SEQ ID NO.10-12, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.10-12; the amino acid sequences of the complementary determining regions CDR1 and CDR3 on the light chain of the monoclonal antibody 4G3 are respectively as shown in SEQ ID NO.13 and SEQ ID NO.14, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.13-14; the amino acid sequence of the complementary determining region CDR2 on the light chain of the monoclonal antibody 4G3 is AAS; The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain of the monoclonal antibody 8D6 are respectively shown in SEQ ID NO.19-21, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.19-21; the amino acid sequences of the complementary determining regions CDR1 and CDR3 on the light chain of the monoclonal antibody 8D6 are respectively shown in SEQ ID NO.22 and SEQ ID NO.23, or have at least 95% sequence identity with the sequences shown in SEQ ID NO.22-23, and the amino acid sequence of the complementary determining region CDR2 on the light chain of the monoclonal antibody 8D6 is RAS.
2. The high-affinity rabbit monoclonal antibody against FMC63 according to claim 1, characterized in that: The amino acid sequence of the heavy chain variable region of the monoclonal antibody 6A7 is shown in SEQ ID NO.6, and the amino acid sequence of the light chain variable region of the monoclonal antibody 6A7 is shown in SEQ ID NO.7; The amino acid sequence of the heavy chain variable region of the monoclonal antibody 4G3 is shown in SEQ ID NO.15, and the amino acid sequence of the light chain variable region of the monoclonal antibody 4G3 is shown in SEQ ID NO.16; The amino acid sequence of the heavy chain variable region of the monoclonal antibody 8D6 is shown in SEQ ID NO.24, and the amino acid sequence of the light chain variable region of the monoclonal antibody 8D6 is shown in SEQ ID NO.
25.
3. The high-affinity rabbit monoclonal antibody against FMC63 according to claim 2, characterized in that: The amino acid sequence of the heavy chain of the monoclonal antibody 6A7 is shown in SEQ ID NO.8, and the amino acid sequence of the light chain of the monoclonal antibody 6A7 is shown in SEQ ID NO.9; The amino acid sequence of the heavy chain of the monoclonal antibody 4G3 is shown in SEQ ID NO.17, and the amino acid sequence of the light chain of the monoclonal antibody 4G3 is shown in SEQ ID NO.18; The amino acid sequence of the heavy chain of the monoclonal antibody 8D6 is shown in SEQ ID NO.24, and the amino acid sequence of the light chain of the monoclonal antibody 8D6 is shown in SEQ ID NO.
25.
4. A substance, characterized in that The substance includes any one of the following aspects: (1) A nucleic acid molecule or a vector comprising the nucleic acid molecule, wherein the nucleic acid encodes the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3; (2) A modified cell or recombinant strain, wherein the modified cell or recombinant strain is used to express the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3; (3) An antibody derivative, comprising the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3; (4) A pharmaceutical composition comprising a therapeutically effective amount of the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3, or the antibody derivative; (5) A detection product, comprising the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3, or the nucleic acid molecule, or the vector, or a derivative of the high-affinity rabbit monoclonal antibody.
5. Use of the high-affinity rabbit monoclonal antibody against FMC63 according to any one of claims 1 to 3, characterized in that: The application includes any one of the following aspects: (1) Detection of FMC63 antibody expression for purposes other than disease diagnosis and treatment; (2) Used for testing the efficacy of CAR-T cells expressing FMC63 antibodies for purposes other than disease diagnosis and treatment; (3) Used to prepare products for detecting the expression of FMC63 antibodies; or, used to prepare products for regulating the activity of FMC63 antibodies; or, used to prepare products for detecting the efficacy of CAR-T cells expressing FMC63 antibodies.
6. The use according to claim 5, characterized in that: Flow cytometry was used to detect the expression of FMC63 antibody in CAR-T cells.
7. The use according to claim 5, characterized in that: The product is a detection reagent, a detection kit, a detection test strip, a detection probe or a detection chip.
